Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Nuvation Bio Inc.
NYSE:NUVBHealthcare · Biotechnology
-2.77%$4.57
AH Close$4.57+0.00%vs close
AH Close$4.57+0.00%vs close
Mkt Cap$1.6B
Float264.01M
O/S351.12M
Inst Own66.7%
SI22.3%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$62.9M
Net Income-$204.63M
Total Assets$594.82M
Free Cash Flow-$173.78M
Debt & Equity
Debt 3%
Equity 97%
Total Debt$10.15M
Total Equity$305.72M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NUVB's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$594.82M
Liabilities$289.11M
Accounts Receivable$19.36M
Accounts Payable$9.48M
Inventory$11.41M
PP&E (Net)$4.48M
Goodwill$0
Intangible Assets$11.21M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $62.9M | $7.87M | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 699.0% | - | - | - | - | - | - | - |
| Cost of Revenue | $8.44M | $7.08M | $0 | $0 | $0 | $103K | $0 | $0 |
| Gross Profit | $54.46M | $795K | $0 | $0 | $0 | -$103K | $0 | $0 |
| Gross Margin | 86.6% | 10.1% | - | - | - | - | - | - |
| Research and Development | $115.11M | $524.19M | $71.29M | $87.81M | $69.04M | $32.6M | $25.11M | $483K |
| Selling, General, and Administrative | $151.56M | $69.23M | $28.53M | $31.92M | $24.28M | $10.85M | $6.99M | $509K |
| Other | $856K | $0 | $0 | $0 | $0 | $0 | -$1 | $0 |
| Total Operating Expenses | $267.52M | $593.42M | $99.82M | $119.73M | $93.32M | $43.45M | $32.1M | $992K |
| Operating Income (EBIT) | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M | -$43.55M | -$32.1M | -$992K |
| Operating Margin | -338.7% | -7527.3% | - | - | - | - | - | - |
| Interest Expense | $13.68M | $341K | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $21.43M | $27.06M | $24.61M | $7.45M | $2.96M | $1.95M | $1K | $0 |
| Other Income (Expense) | $8.44M | $24.69M | $24.02M | $15.54M | $6.47M | $1.89M | -$1.45M | $0 |
| Income Before Tax (EBT) | -$204.63M | -$567.94M | -$75.8M | -$104.2M | -$86.85M | -$41.66M | -$33.55M | -$992K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$204.63M | -$567.94M | -$75.8M | -$104.2M | -$86.85M | -$41.66M | -$33.55M | -$992K |
| Net Income Margin | -325.3% | -7213.8% | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | -0.19 | -0.16 | -0.01 |
| Diluted EPS | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 | -0.19 | -0.16 | -0.01 |
| Weighted Average OS | 341.54M | 268.77M | 218.88M | 216.72M | 197.89M | 217.65M | 206.67M | 183.74M |
| EBITDA | -$189.21M | -$566.91M | -$75.58M | -$104M | -$86.66M | -$41.56M | -$32.09M | $0 |
| EBITDA Margin | -300.8% | -7200.7% | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $164.09M | $35.72M | $42.65M | $101.1M | $132.42M | $29.75M | $3.47M | $138K |
| Short-Term Investments | $365.13M | $466.97M | $568.56M | $559.91M | $632.97M | $186M | $115.4M | $0 |
| Cash and Short-Term Investments | $529.21M | $502.69M | $611.21M | $661.01M | $765.39M | $215.75M | $118.87M | $138K |
| Accounts Receivable | $19.36M | $16.29M | $3.7M | $2.48M | $3.04M | $1.09M | $0 | $0 |
| Inventory | $11.41M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $11.54M | $7.27M | $1.52M | $3.82M | $0 | $2.92M | $828K | $0 |
| Total Current Assets | $571.52M | $526.25M | $616.43M | $667.32M | $772.07M | $220.68M | $119.89M | $158K |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $4.48M | $2.99M | $4.32M | $4.68M | $3.66M | $688K | $646K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $11.21M | $4.62M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $7.61M | $6.76M | $728K | $138K | $421K | $421K | $421K | $0 |
| Total Long-Term Assets | $23.3M | $14.37M | $5.05M | $4.82M | $4.08M | $1.11M | $1.07M | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M | $221.79M | $120.95M | $158K |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $9.48M | $6.35M | $2.21M | $2.14M | $3.92M | $2.17M | $2.03M | $83K |
| Short-Term Debt | $7.6M | $6.28M | $0 | $0 | $0 | $0 | $0 | $600K |
| Current Income Tax Payable | $0 | $679K | $144K | $112K | $402K | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $11.12M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $65.15M | $14.82M | $4.35M | $3.99M | $6.17M | $3.23M | $11K | $0 |
| Total Current Liabilities | $82.23M | $58.24M | $13.97M | $13.16M | $16.93M | $6.55M | $3.2M | $902K |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $2.54M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $145.82M | $15.57M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $58.51M | $2.05M | $353K | $850K | $11.04M | $157K | $0 | $0 |
| Total Long-Term Liabilities | $206.88M | $18.59M | $2.39M | $3.9M | $13.23M | $157K | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $289.11M | $76.84M | $16.36M | $17.07M | $30.15M | $6.71M | $3.2M | $902K |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $141.86M | $0 |
| Common Stock | $1.42B | $1.37B | $947.75M | $927.6M | $909.99M | $289.48M | $9.76M | $0 |
| Retained Earnings | -$1.12B | -$910.74M | -$342.8M | -$267M | -$162.8M | -$75.95M | -$34.3M | -$744K |
| Comprehensive Income & Other | -$187K | $573K | $181K | -$5.53M | -$1.19M | $1.56M | $421K | $0 |
| Other Stockholders' Equity | -$187K | $573K | $181K | -$5.53M | -$1.19M | $1.56M | $142.28M | $0 |
| Total Equity | $305.72M | $463.79M | $605.12M | $655.08M | $746M | $215.08M | $117.75M | -$744K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M | $221.79M | $120.95M | $158K |
| Supplementary Data | ||||||||
| Total Debt | $10.15M | $8.91M | $4.01M | $4.26M | $3.06M | $0 | $0 | $600K |
| Net Debt | -$153.94M | -$26.81M | -$38.64M | -$96.84M | -$129.37M | -$29.75M | -$3.47M | $462K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$204.63M | -$567.94M | -$75.8M | -$104.2M | -$86.85M | -$41.66M | -$33.55M | -$992K |
| Depreciation & Amortization | $1.74M | $683K | $222K | $199K | $184K | $103K | $13K | $992K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $35.89M | $32.27M | $19.51M | $16.29M | $9.27M | $2.2M | $0 | $0 |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | -$3.07M | -$12.59M | -$1.22M | $554K | -$1.95M | -$264K | $0 | $0 |
| Inventory | -$11.41M | $0 | $0 | $0 | $0 | $264K | $0 | $0 |
| Accounts Payable | $3.13M | -$1.65M | $70K | -$1.79M | $1.86M | $34K | $0 | $0 |
| Other Working Capital | -$630K | $1.74M | $1.69M | -$2.21M | $4.88M | $2.08M | -$460K | $265K |
| Total Working Capital Change | -$11.98M | -$12.51M | $540K | -$3.45M | $4.79M | $2.11M | -$460K | $265K |
| Other Non-Cash Items | $5.55M | $417.07M | -$12.47M | -$4.95M | $4.41M | $715K | $9.57M | -$881K |
| Net Cash from Operating | -$173.43M | -$130.41M | -$68M | -$96.11M | -$68.19M | -$36.53M | -$24.43M | -$616K |
| Investing Activities | ||||||||
| Capital Expenditures | -$8.35M | -$162K | -$69K | -$370K | -$282K | -$145K | -$659K | $0 |
| Acquisitions | $0 | $12.43M | $0 | $0 | $0 | -$2.51M | $0 | $0 |
| Purchases of Investments | -$354.42M | -$339.64M | -$703.37M | -$520.31M | -$609.3M | -$143.29M | $0 | $0 |
| Sales of Investments | $462.29M | $450.08M | $712.35M | $584.12M | $154.91M | $73.11M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $14K | $13K | $0 | $2.51M | -$115.2M | $0 |
| Net Cash from Investing | $99.52M | $122.7M | $8.92M | $63.46M | -$454.67M | -$70.32M | -$115.86M | $0 |
| Financing Activities | ||||||||
| Debt Repaid | -$191.11M | - | - | - | - | - | -$14.99M | - |
| Common Stock Issuance | $11.42M | $4.88M | $0 | $0 | $0 | $135.66M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $628K | $1.33M | $625.53M | -$2.52M | $128.63M | $800K |
| Net Cash from Financing | $202.53M | $331K | $628K | $1.33M | $625.53M | $133.13M | $143.62M | $800K |
| Forex Effect | -$265K | $453K | $0 | $0 | $0 | $0 | $138 | $0 |
| Net Change in Cash | $128.36M | -$6.93M | -$58.45M | -$31.32M | $102.67M | $26.29M | $3.33M | $184K |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$173.43M | -$130.41M | -$68M | -$96.11M | -$68.19M | -$36.53M | -$24.43M | -$616K |
| Capital Expenditure | -$354K | -$162K | -$69K | -$370K | -$282K | -$145K | -$659K | $0 |
| Free Cash Flow | -$173.78M | -$130.57M | -$68.07M | -$96.48M | -$68.47M | -$36.67M | -$25.09M | -$616K |
| Cash at Beginning | $35.72M | $42.65M | $101.1M | $132.42M | $29.75M | $3.47M | $138K | $0 |
| Cash at End | $164.09M | $35.72M | $42.65M | $101.1M | $132.42M | $29.75M | $3.47M | $184K |